A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Trial Profile

A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Sapanisertib (Primary) ; Pazopanib
  • Indications Leiomyosarcoma; Malignant-fibrous-histiocytoma; Nerve sheath neoplasms; Sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2017 Status changed from suspended to recruiting.
    • 14 Sep 2017 Planned primary completion date changed from 31 Jul 2017 to 1 Sep 2020.
    • 07 Aug 2017 Status changed from recruiting to suspended due to unacceptable Toxicity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top